Has Hirsch Mehta, MD received payments from drug or device companies?

Yes. Drug and device makers reported $845,200 in general payments to Hirsch Mehta, MD across 1,313 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hirsch Mehta, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hirsch Mehta, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hirsch Mehta, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1407099799

Payments from drug & device makers

$845,200in general payments, 2019–2025

Across 1,313 payments — averaging $643.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$206K
Actelion Pharmaceuticals US, Inc.$116K
Boehringer Ingelheim Pharma GmbH & Co.kg$75K
Merck$74K
Boehringer Ingelheim International GmbH$59K
Boehringer Ingelheim$56K
plus $260K from 47 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	92	$206,194
Actelion Pharmaceuticals US, Inc.	399	$115,866
Boehringer Ingelheim Pharma GmbH & Co.kg	6	$74,820
Merck	70	$73,944
Boehringer Ingelheim International GmbH	8	$58,888
Boehringer Ingelheim	79	$55,734
Alnylam Pharmaceuticals Inc.	57	$35,351
E.r. Squibb & Sons, L.L.C.	55	$29,976
Bayer	55	$29,782
AstraZeneca	63	$22,863
Janssen Research & Development, LLC	5	$22,619
Pfizer	95	$22,516
Lilly USA, LLC	21	$21,582
Amgen	12	$19,647
Edwards Lifesciences	4	$16,239
Akcea Therapeutics, Inc.	12	$15,326
Bridgebio Pharma, Inc.	15	$13,738
Abbott	60	$5,312
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	78	$1,355
Medtronic(2 entities)	6	$455
Novartis	25	$418
Abiomed	4	$309
Cvrx, Inc.	8	$256
Johnson & Johnson	16	$249
United Therapeutics Corporation	6	$214
Biosense Webster, Inc.	2	$167
Cathworks, Inc.	3	$152
Novo Nordisk	7	$151
Heartflow, Inc.	5	$129
Getinge USA Sales, LLC	3	$120
Nuwellis, Inc.	2	$108
Kestra Medical Technology Services, Inc.	4	$95
Esperion Therapeutics, Inc.	5	$70
Irhythm Technologies, Inc.	3	$55
Regeneron Healthcare Solutions, Inc.	4	$55
Scpharmaceuticals Inc.	3	$52
Daiichi Sankyo Inc.	2	$47
Kiniksa Pharmaceuticals, Ltd.	2	$39
Chiesi USA, Inc.	2	$36
Terumo Medical Corporation	1	$33
Impulse Dynamics (USA) Inc.	1	$30
Astellas Pharma US Inc	1	$23
Tactile Systems Technology Inc	2	$23
Amarin Pharma, Inc.	1	$22
Biotronik Inc.	1	$22
Gilead	1	$18
Lexicon Pharmaceuticals, Inc.	1	$17
Sobi, Inc	1	$16
Trevena, Inc.	1	$16
Kiniksa Pharmaceuticals International, PLC	1	$14
Arbor Pharmaceuticals, Inc.	1	$14
Sanofi-aventis U.S. LLC	1	$11
Altathera Pharmaceuticals LLC	1	$10

How this compares

$845,200 in reported general payments places this provider in the 85th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California →

Medicare billing

Part B allowed, 2024

$544,426

Medicare patients

960

Services billed

5,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other advanced heart failure and transplant cardiology in San Diego

Eric AdlerSan Diego$1.4M
Marcus UreySan Diego$987K
Brian JaskiSan Diego$662K
Jorge Silva EncisoSan Diego$580K
Barry GreenbergSan Diego$322K
Hao TranSan Diego$319K
Peter HoaglandSan Diego$242K
Ajay SrivastavaSan Diego$203K
Burhan MohamedaliSan Diego$174K
Justin ParizoSan Diego$104K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →